Despite use of tecovirimat since the beginning of the 2022 mpox outbreak, few data have been published on its antiviral effect in humans

The Study of Tecovirimat for Mpox (STOMP) trial found that tecovirimat was safe but did not improve mpox resolution or pain in adults with mild to moderate clade II mpox. The study recommended stopping further enrollment due to the lack of efficacy signal.

The Study of Tecovirimat for Mpox (STOMP) trial found that tecovirimat did not reduce the time to clinical resolution of clade II mpox lesions or improve pain control. The antiviral drug was shown to be safe but ineffective in treating clade II mpox.

A study examining tecovirimat's effectiveness on mpox in the DRC found the drug safe but showed no significant impact on lesion duration. The trial, sponsored by the NIH and co-led with the DRC, resulted in lower mortality rates among participants compared to reported cases.

A new study published in Nature reveals that mpox was circulating among humans in Nigeria for eight years before the international outbreak in 2022. The research team analyzed 118 viral genomes from human mpox cases and found that most of the samples were the result of human-to-human transmission.

Researchers at the Institut Pasteur have gained a better understanding of how mpox variants become resistant to tecovirimat. They found that the drug works by binding two phospholipases together, preventing viral particles from spreading. This knowledge will help develop new antiviral treatments effective across all mpox strains.

The 2022-2023 mpox outbreak in the Netherlands declined due to infection-induced immunity in high-risk groups, highlighting the importance of prompt vaccination implementation and ongoing surveillance. The study recommends swift vaccination programs and continuous monitoring to mitigate future outbreaks.